Clinical trials: Intranasal Administration
Body Dysmorphic Disorder, Obsessive-compulsive Disorder
Oxytocin Administration in BDD and OCD
The purpose of the current study is to investigate the effect of an acute administration of intranasal oxytocin, relative to placebo, on social cognitive impairments among individuals with body dysmorphic disorder and…
- Trial name
- NCT02671266
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Asthma
Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
- Trial name
- NCT05363670
- Testing
- ARS-1 1 mg, Albuterol MDI, ARS-1 2mg
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- ARS Pharmaceuticals, Inc.
Treatment Resistant Depressive Disorder
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
The purpose of this study is to assess the efficacy and dose response of intranasal esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with placebo in improving depressive symptoms in participants…
- Trial name
- SYNAPSE (NCT01998958)
- Testing
- Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg
- Where
- 25 sites in United States, Belgium and 1 more
- Volunteers
- 108 people
- Sponsor
- Janssen Research & Development, LLC
Hypogonadism
Efficacy of an Intranasal Testosterone Product
This clinical trial will compare the pharmacokinetic profile of testosterone after repeated intranasal administration of TBS-1 of different strengths in subjects with hypogonadism
- Trial name
- NCT01252745
- Testing
- 10.0 mg of Testosterone, 4.0% TID, 13.5 mg of Testosterone, 4.5% B.I.D, 11.25 mg of Testosterone, 4.5% T.I.D
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Acerus Pharmaceuticals Corporation
Healthy Volunteers
Tolerability, Safety and Pharmacokinetics of Four Formulations of Ketorolac Tromethamine in Healthy Volunteers
This was a phase 1, double-blind, 4-way crossover study in healthy male and female volunteers. Subjects received 4 formulations of intranasal ketorolac tromethamine 30 mg.
- Trial name
- NCT01355588
- Testing
- Ketorolac Tromethamine, Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl), Ketorolac Tromethamine with 5% Lidocaine HCl
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Egalet Ltd
Mood Disorder, Anxiety Disorders
Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers
There is growing evidence that neuropeptides act as neuronal messengers in the brain and have diverse functions that may include the regulation of mood and behavior.
- Trial name
- NPY (NCT00748956)
- Testing
- Low dose NPY, High dose NPY
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Dennis Charney
Chronic Migraine
Study to Evaluate the Efficacy of Intranasal Kinetic Oscillation Stimulation in the Preventive Treatment of Chronic Migraine
The efficacy of intranasal kinetic oscillation stimulation using the Chordate System S211 as a preventative treatment will be examined in patients diagnosed with chronic migraine.
- Trial name
- NCT03400059
- Testing
- Chordate System S211 in treatment mode
- Where
- 10 sites in Finland, Germany
- Volunteers
- 144 people
- Sponsor
- Chordate Medical
Migraine
Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children
Ketorolac is an evidence-based, first-line acute migraine therapy that is commonly used in the pediatric population; however, it is typically administered by the intravenous (IV) or intramuscular (IM) routes, both of which…
- Trial name
- NCT02358681
- Testing
- Ketorolac, intranasal, Ketorolac, intravenous
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Columbia University
Urticaria
Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares
Determine the effect of ARS-1 on a patient reported pruritus/hive score
- Trial name
- NCT05496465
- Testing
- ARS-1
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- ARS Pharmaceuticals, Inc.
Treatment-resistant Depression
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
The purpose of this open-label, multicenter study is to assess the long term safety and efficacy of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD).
- Trial name
- SUSTAIN-2 (NCT02497287)
- Testing
- Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 109 sites in United States, Argentina and 19 more
- Volunteers
- 802 people
- Sponsor
- Janssen Research & Development, LLC
Paranoia, Schizophrenia
Oxytocin Treatment of Schizophrenia
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, social functioning and decreases paranoia and other psychotic symptoms in schizophrenia.
- Conditions
- Paranoia, Schizophrenia, Schizoaffective Disorder
- Trial name
- OTS (NCT01028677)
- Testing
- intranasal spray with oxytocin, nasal spray without oxytocin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Tinnitus
High Dose Oxytocin Nasal Spray for Treatment of Tinnitus
The purpose of this study is to evaluate the effects of high-dose intranasal oxytocin for treating tinnitus. The hypothesis is that high dose intranasal oxytocin can significantly reduce tinnitus severity and disability.
- Trial name
- NCT04210310
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- NYU Langone Health
Epilepsy
Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters
The purpose of this study is to examine the safety and effectiveness of USL261 for the outpatient treatment of seizure clusters.
- Trial name
- ARTEMIS1 (NCT01390220)
- Testing
- USL261
- Where
- 90 sites in United States, Australia and 9 more
- Volunteers
- 292 people
- Sponsor
- UCB Biopharma S.P.R.L.
Rhinitis, Allergic, Perennial
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with…
- Trial name
- NCT00289198
- Testing
- FF
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 301 people
- Sponsor
- GlaxoSmithKline
Drug Overdose
A Usability Assessment of Naloxone by Community Members
This will be a usability trial to assess administration of naloxone via intramuscular, atomized intranasal, and nasal spray routes by nonmedical community members.
- Trial name
- NCT03309449
- Testing
- Syringe and needle, Intranasal mucosal atomization device, Nasal spray
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
Influenza
Home Administration of FluMist by Parents/Caregivers
This study will examine the feasibility of having parents and caregivers administer FluMist live intranasal vaccine to their children at home outside the traditional medical environment and without the involvement of medical…
- Trial name
- NCT01938170
- Testing
- FluMist
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Bilateral Nasal Polyposis
Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device
The primary objective of this study was to compare the efficacy of intranasal administration of 100, 200, and 400 μg twice daily (bid) of fluticasone propionate, delivered by the Optinose device, with matching placebo in subjects…
- Trial name
- NCT01624662
- Testing
- Fluticasone propionate
- Where
- 10 sites in United States
- Volunteers
- 323 people
- Sponsor
- Optinose US Inc.
Pharmacokinetics
Pharmacokinetic Evaluation of Intranasal Nalmefene
This study is to determine the pharmacokinetics (how the body absorbs, breaks down and eliminates drug from your body) of nalmefene when given intranasally (IN;into the nose) compared to a dose of nalmefene when given…
- Trial name
- NCT04759768
- Testing
- Nalmefene Hydrochloride, Nalmefene
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Opiant Pharmaceuticals Inc
Chronic Sinusitis With or Without Nasal Polyps
Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps
This is an open-label, multicenter study designed to assess the safety of intranasal administration of 400 μg of fluticasone propionate twice a day delivered by the OptiNose device in subjects with chronic sinusitis with or…
- Trial name
- NCT01623323
- Testing
- Fluticasone Propionate
- Where
- 18 sites in United States
- Volunteers
- 705 people
- Sponsor
- Optinose US Inc.
Anemia, Sickle Cell, Pain
Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis
The purpose of this study is to determine if intranasal fentanyl can decrease the pain of patients with sickle cell disease who present to the pediatric emergency department with a vaso-occlusive crisis.
- Trial name
- NCT01482091
- Testing
- Fentanyl Citrate, Normal Saline
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Montefiore Medical Center